refludan and Klebsiella-Infections

refludan has been researched along with Klebsiella-Infections* in 1 studies

Other Studies

1 other study(ies) available for refludan and Klebsiella-Infections

ArticleYear
Combination of antibiotic treatment with the thrombin inhibitor recombinant hirudin for the therapy of experimental Klebsiella pneumoniae sepsis.
    Thrombosis and haemostasis, 1994, Volume: 71, Issue:6

    Rats which were infected with the gramnegative pathogen Klebsiella pneumoniae develop disseminated intravascular coagulation (DIC), multi-organ failure (MOF) and finally die in a septic shock. We investigated the therapeutic effect of antibiotic (tobramycin) treatment combined with the infusion of the highly specific thrombin inhibitor rec. hirudin. Although administration of 2 mg/kg tobramycin alone leads to a decrease of the bacterial burden, DIC could not be prevented. Infusion of rec. hirudin (0.25 mg/kg x h) for 4 h (start of treatment 1 h post infection), in addition to a bolus administration of tobramycin, led to an amelioration of DIC parameters as fibrinogen, thrombin-antithrombin complex (TAT) and platelets. Serum transaminase levels (GOT, GPT) as a marker of MOF were significantly improved by rec. hirudin, the T50 value increased from 17 h in the tobramycin group to 42 h in the tobramycin+rec. hirudin group, mortality rates were 90% or 60%, respectively. Combination of heparin (100 U/kg x h) and tobramycin was not effective on survival.

    Topics: Animals; Disseminated Intravascular Coagulation; Drug Therapy, Combination; Female; Hirudin Therapy; Hirudins; Klebsiella Infections; Klebsiella pneumoniae; Multiple Organ Failure; Rats; Recombinant Proteins; Sepsis; Tobramycin

1994